Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

This study has been completed.

Sponsored by:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00168363

Purpose

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Condition	Intervention	Phase
Glaucoma Ocular Hypertension	Drug: brimonidine	Phase III

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Brimonidine Brimonidine Tartrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Allergan:

Primary Outcome Measures:

lowering of intraocular pressure

Estimated Enrollment:

150

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

ocular hypertension or glaucoma in both eyes
currently treated with brimonidine
requires IOP-lowering therapy in both eyes

Exclusion Criteria:

uncontrolled systemic disease
known allergy or sensitivity to brimonidine

Contacts and Locations

No Contacts or Locations Provided

More Information

Link to Clinical Trial Results This link exits the ClinicalTrials.gov site

Publications indexed to this study:

Cantor LB, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin. 2008 Jul;24(7):2035-43. Epub 2008 Jun 4.

Study ID Numbers:	190342-022
Study First Received:	September 12, 2005
Last Updated:	April 1, 2008
ClinicalTrials.gov Identifier:	NCT00168363
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Vascular Diseases

Brimonidine
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents
Adrenergic alpha-Agonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Therapeutic Uses
Physiological Effects of Drugs

Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Adrenergic Agonists

ClinicalTrials.gov processed this record on January 13, 2009